Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 L-dopa and amantadine hydrochloride in extra-pyramidal disorders.

Literature DB >> 5572526

L-dopa and amantadine hydrochloride in extra-pyramidal disorders.

J D Parkes, R P Knill-Jones, P J Clements.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1971 PMID： 5572526 PMCID： PMC2467156 DOI： 10.1136/pgmj.47.544.116

Source DB: PubMed Journal: Postgrad Med J ISSN： 0032-5473 Impact factor: 2.401

× No keyword cloud information.

12 in total

1. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.

Authors: J R Mendell; W K Engel; T N Chase
Journal: Lancet Date: 1970-03-21 Impact factor: 79.321

2. Treatment of Wilson's disease with L-dopa after failure with penicillamine.

Authors: A Barbeau; H Friesen
Journal: Lancet Date: 1970-05-30 Impact factor: 79.321

3. Modification of Parkinsonism--chronic treatment with L-dopa.

Authors: G C Cotzias; P S Papavasiliou; R Gellene
Journal: N Engl J Med Date: 1969-02-13 Impact factor: 91.245

4. L-dopa and juvenile Huntington's disease.

Authors: A Barbeau
Journal: Lancet Date: 1969-11-15 Impact factor: 79.321

Review 5. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration.

Authors: M Victor; R D Adams; M Cole
Journal: Medicine (Baltimore) Date: 1965-09 Impact factor: 1.889

6. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane.

Authors: I Mena; J Court; S Fuenzalida; P S Papavasiliou; G C Cotzias
Journal: N Engl J Med Date: 1970-01-01 Impact factor: 91.245

7. The toxicologic and pharmacologic properties of amantadine hydrochloride.

Authors: V G Vernier; J B Harmon; J M Stump; T E Lynes; J P Marvel; D H Smith
Journal: Toxicol Appl Pharmacol Date: 1969-11 Impact factor: 4.219

8. Amantadine-dopamine interaction: possible mode of action in Parkinsonism.

Authors: R P Grelak; R Clark; J M Stump; V G Vernier
Journal: Science Date: 1970-07-10 Impact factor: 47.728

Review 9. Dopamine (3-hydroxytyramine) and brain function.

Authors: O Hornykiewicz
Journal: Pharmacol Rev Date: 1966-06 Impact factor: 25.468

10. Progressive supranuclear palsy. Clinico-pathological study of four cases.

Authors: S Behrman; J D Carroll; I Janota; W B Matthews
Journal: Brain Date: 1969 Impact factor: 13.501

4 in total

Review 1. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors: R N Brogden; T M Speight; G S Avery
Journal: Drugs Date: 1971 Impact factor: 9.546